SYDNEY, AUSTRALIA - Immutep Limited (ASX:IMM; NASDAQ:IMMP) (“Immutep” or “the Company”) is pleased to announce that it has submitted its Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”) for eftilagimod alpha (“efti” or “IMP321”) in June 2018.
If granted by the FDA, the IND application will allow Immutep to ship efti across U.S. State borders to U.S. clinical investigators participating in the Company’s planned TACTI-002 Phase II clinical study, making it an important step in the clinical trial preparations. This is the first IND application for efti in the U.S. following the encouraging pre-IND meeting in November last year.
For further information please download PDF attached:
Download this document
